Sugi Predict

Sugi Predict / Targets / NCEH1

NCEH1

Neutral cholesterol ester hydrolase 1 · Q6PIU2 · NCEH1 on Sugi Atlas →

10,428 patent compounds predicted against NCEH1, 4,168 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL830202 SCHEMBL830202 1.00 18/20
SCHEMBL829483 SCHEMBL829483 0.66 16/20
SCHEMBL2470633 SCHEMBL2470633 0.74 13/20
SCHEMBL829420 SCHEMBL829420 0.67 13/20
SCHEMBL829227 SCHEMBL829227 0.72 12/20
SCHEMBL1709119 SCHEMBL1709119 0.62 12/20
SCHEMBL1699754 SCHEMBL1699754 0.51 12/20
SCHEMBL1709101 SCHEMBL1709101 0.49 12/20
Zinc Ion Zinc Ion (SCHEMBL536405) 0.55 11/20
SCHEMBL594455 SCHEMBL594455 0.54 11/20
SCHEMBL2467190 SCHEMBL2467190 0.54 11/20
SCHEMBL2198922 SCHEMBL2198922 0.51 11/20
SCHEMBL2055410 SCHEMBL2055410 0.58 9/20
SCHEMBL829421 SCHEMBL829421 0.53 9/20
SCHEMBL2090835 SCHEMBL2090835 0.47 9/20
SCHEMBL2090833 SCHEMBL2090833 0.42 9/20
SCHEMBL1502327 SCHEMBL1502327 0.57 8/20
SCHEMBL536406 SCHEMBL536406 0.56 8/20
Lonaprofen Lonaprofen (SCHEMBL2109183) 0.56 8/20
SCHEMBL2690158 SCHEMBL2690158 0.49 8/20

Clinical trials — most relevant to NCEH1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Efficacy of Miglustat in Chinese NPC Patients PHASE4COMPLETED
Bezafibrate Trial in CPT2 Deficiency PHASE3UNKNOWN
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism PHASE2COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects PHASE1COMPLETED
Improving Metabolism With HDL Cholesterol nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification nanCOMPLETED
Identification of Genes Predisposing to Atherosclerosis nanCOMPLETED
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype nanCOMPLETED
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
The Roles of SAH Gene Family in Athrogenic Dyslipidemia in Postmenopausal Women nanUNKNOWN
Effect of Bariatric Surgery on Bile Acid Homeostasis nanCOMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
Abnormal Lipids - Causes and Effects nanRECRUITING
Genetic Epidemiology of Blood Lipids and Obesity - Ancillary to NGHS nanCOMPLETED
Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals nanCOMPLETED
Genomic Dissection of a QTL Affecting the Lipid Profile nanWITHDRAWN
Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia nanCOMPLETED
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials nanRECRUITING
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL) nanCOMPLETED
Lysosomal Acid Lipase (LAL) Deficiency Registry nanRECRUITING
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
Genes Involved in Lipid Disorders nanCOMPLETED
Genetic Origin of Lipid Disorders nanUNKNOWN
Impact Of Choline in Patients With NAFLD nanUNKNOWN
Study of Inborn Errors of Cholesterol Synthesis and Related Disorders nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NCEH1 binder may also engage these)

ProteinNameSimilarity
Q5R8Y5 — 1.000 Q5R8Y5 →
Q1JQE6 — 0.995 Q1JQE6 →
Q8BLF1 — 0.982 Q8BLF1 →
B2GV54 — 0.970 B2GV54 →
Q91ZH7 — 0.947 Q91ZH7 →
TECR Very-long-chain enoyl-CoA reductase 0.930 landscape →
Q9H6U8 — 0.929 Q9H6U8 →
Q3ZCD7 — 0.928 Q3ZCD7 →
Q9JMF7 — 0.922 Q9JMF7 →
Q96NT3 — 0.922 Q96NT3 →
B2KI79 — 0.922 B2KI79 →
Q86YN1 — 0.922 Q86YN1 →
B1MTH4 — 0.921 B1MTH4 →
Q6ICL3 — 0.921 Q6ICL3 →
Q13888 — 0.921 Q13888 →
B0KWE9 — 0.921 B0KWE9 →
Q2HJ19 — 0.921 Q2HJ19 →
Q2TBV5 — 0.920 Q2TBV5 →
Q6P1K8 — 0.920 Q6P1K8 →
Q8BZI6 — 0.920 Q8BZI6 →
Q5SP67 — 0.920 Q5SP67 →
F1LTR1 — 0.919 F1LTR1 →
Q8VDI9 — 0.919 Q8VDI9 →
B0CM95 — 0.918 B0CM95 →
Q0VC00 — 0.917 Q0VC00 →
CBR1 Carbonyl reductase [NADPH] 1 0.916 landscape →
Q9CY27 — 0.916 Q9CY27 →
PAICS Bifunctional phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase 0.916 landscape →
Q9JIB4 — 0.915 Q9JIB4 →
Q5ZIN0 — 0.915 Q5ZIN0 →